Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective.Methods: A st...

Full description

Bibliographic Details
Main Authors:	Zhe Liang, Qi Chen, Ruiqi Wei, Chenyao Ma, Xuehui Zhang, Xue Chen, Fang Fang, Quanming Zhao
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Pharmacology
Subjects:	alirocumab cost-effectiveness myocardial infarction PCSK9 inhibitors secondary prevention
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.648244/full

Similar Items

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
by: Rana K, et al.
Published: (2019-09-01)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk
by: Dirk Müller-Wieland, et al.
Published: (2017-05-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Breaking Therapeutic Inertia With Alirocumab in an 80-Year-Old Patient With Severe Hypercholesterolemia: A Case Report
by: Angela Dardano, et al.
Published: (2021-07-01)

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol
by: Helen M. Colhoun, et al.
Published: (2020-02-01)

Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials
by: Ajay K Shukla, et al.
Published: (2019-01-01)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017-08-01)

Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale
by: Tamio Teramoto, et al.
Published: (2017-06-01)

Economic expertise of alirocumab in standard lipid lowering therapy insusceptibility
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)
by: Bass, K., et al.
Published: (2022)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
by: Ioanna Gouni-Berthold, et al.
Published: (2014-12-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
by: Edyta Kinga Prokop, et al.
Published: (2019-04-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

Circulating PCSK9 and Risk of Myocardial Infarction
by: Lars E. Laugsand, MD, PhD, et al.
Published: (2016-12-01)

Effects of alirocumab on cardiovascular events and all-cause mortality: a systematic review and meta-analysis
by: Wanting Wang, et al.
Published: (2021-09-01)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
by: Ioanna Andreadou, et al.
Published: (2020-11-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
by: José Seijas-Amigo, et al.
Published: (2021-05-01)

Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study
by: Chang-Wook Nam, et al.
Published: (2019-11-01)

What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
by: Remo H. M. Furtado, et al.
Published: (2020-02-01)

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
by: Jetty V, et al.
Published: (2017-07-01)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017-05-01)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
by: Gema Miñana, et al.
Published: (2020-02-01)

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial
by: Yu. A. Karpov
Published: (2019-01-01)

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study
by: Erik Stroes, et al.
Published: (2016-09-01)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
by: Brian Tomlinson, et al.
Published: (2021-04-01)

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
by: Kausik K. Ray, et al.
Published: (2019-11-01)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
by: Hyeon Seok Hwang, et al.
Published: (2020-01-01)

Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography
by: Fei Gao, et al.
Published: (2021-09-01)

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
by: Yousuf Zafar, et al.
Published: (2020-01-01)

Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction
by: Meifan Zheng, et al.
Published: (2020-06-01)

The association between plasma furin and cardiovascular events after acute myocardial infarction
by: Zhi-Wei Liu, et al.
Published: (2021-09-01)

PCSK9: BIOLOGICAL ACTIVITY REGULATION AND CONNECTION WITH LIPID AND CARBOHYDRATE METABOLISM
by: A O Averkova
Published: (2017-09-01)

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
by: Ye-Xuan Cao, et al.
Published: (2019-11-01)

Patients with myocardial infarction
by: Maurer, Jean M.
Published: (2018)

Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction
by: Ballantyne, C.M, et al.
Published: (2022)

FEELINGS EXPERIENCED BY PATIENTS FACED WITH A FIRST EVENT OF MYOCARDIAL INFARCTION
by: M. L. Botelho, et al.
Published: (2015-06-01)

Feelings experienced by patients faced with a first event of myocardial infarction
by: M. L. Botelho, et al.
Published: (2014-10-01)

Cannot write session to /tmp/vufind_sessions/sess_9upaubnlom58gcul3f8slr4k3s